VFA
RAPP

Values First Advisors’s Rapport Therapeutics RAPP Stock Holding History

Values First Advisors’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,507
Closed -$30.9K – 299
2024
Q3 		$30.9K Buy
+1,507
New +$32.4K 0.02% 254

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Values First Advisors's RAPP Position: Q4 2024 in Review

Values First Advisors sold out of Rapport Therapeutics (RAPP) in Q4 2024, closing a stake of 1,507 shares — an estimated $30.9K sold.

Values First Advisors first reported a position in RAPP in Q3 2024 and held it in 1 quarter. The position peaked at $30.9K in Q3 2024. 70 funds tracked by Wall St. Rank hold RAPP as of Q4 2024.

  • Values First Advisors reported no remaining Rapport Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Values First Advisors sold 1,507 Rapport Therapeutics shares in Q4 2024, an estimated $30.9K.
  • Values First Advisors first reported a position in Rapport Therapeutics in Q3 2024 and held it in 1 quarter.
  • Values First Advisors's Rapport Therapeutics position peaked at $30.9K in Q3 2024.
  • 70 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q4 2024.

Based on Values First Advisors's 13F filing for Q4 2024, filed 29 Jan 2025.